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A recombinant cucumber mosaic virus based expression system has been 
developed for the production of an immunogenic porcine circovirus epitope. The 
resulting nanoparticle was shown to elicit specific immune response in mice and 
pigs, when administered parenterally. To evaluate the oral applicability of this 
vaccine candidate, two experiments were performed. In the first one, the resis-
tance of the vector itself to mucosal environment was tested in mice. Cucumber 
mosaic virus particles fed to mice were able to elicit specific mucosal and serum 
antibody production. In the second experiment, recombinant cucumber mosaic vi-
rus fed to piglets resulted in the appearance of porcine circovirus specific serum 
antibodies. The vector proved to be able to survive in the gastrointestinal tract, so 
that an epitope expressed on its surface could induce specific immune response. 
These results indicate that the developed plant virus based expression system of-
fers an effective method for mucosal vaccine production. 
Key words: Cucumber mosaic virus, porcine circovirus, subunit vaccine, 
oral immunisation 
The expression of antigens using plant virus vectors is an inexpensive, ef-
fective and promising method of subunit vaccine production. Many antigens of 
public health and veterinary importance have already been expressed in this way, 
including viral antigens (e.g. human immunodeficiency virus, hepatitis B virus, ra-
bies virus, foot and mouth disease virus, canine parvovirus epitopes), antigens of 
bacterial origin (e.g. Staphylococcus aureus, Yersinia pestis, Mycobacterium tu-
berculosis, Bacillus anthracis) and other vaccine candidates (e.g. Plasmodium fal-
ciparum, B cell lymphoma antigens) (Tiwari et al., 2009). Unlike protein produc-
tion in transgenic plants, this method does not involve genetic modification of 
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plants, the genetic code of the protein or peptide to be expressed is inserted into the 
genome of a virus infecting a host plant. These viruses are easier to manipulate 
than eukaryotic cell genomes, and production yields can be much higher (Hef-
feron, 2012), although the size of the insertable nucleic acids may be limited. Vac-
cines produced in plants are suitable to be used as oral vaccines, offering the ad-
vantage of simple delivery and induction of mucosal immunity (Yusibov et al., 2011). 
One of the vector candidates is cucumber mosaic virus (CMV), a plant 
pathogen of the genus Cucumovirus in the family Bromoviridae, infecting more 
than 1200 species (Mochizuki and Ohki, 2012) including many agriculturally 
important, edible vegetables and ornamental plants. CMV particles are isometric, 
approximately 28–30 nm in diameter, with messenger sense single-stranded 
RNA genomes. The properties of the virus (wide host range, extensively studied 
genome, modes of virus replication, cell-to-cell and systemic movement in 
plants, mechanical transmission between plants) made CMV a promising vector 
candidate for protein production. CMV-based vectors have already been devel-
oped for expression of peptides of interest in human health, namely the R9 hepa-
titis C virus envelope derived epitope (Nuzzaci et al., 2009; Nuzzaci et al., 2010) 
and amyloid β protein fragments (Vitti et al., 2010). 
Porcine circovirus type 2 (PCV2) is a well-known pathogen of wild boars 
and domestic swine, causing major economic losses in the pig industry world-
wide, due to PCV2-associated diseases facilitating the development of secondary 
infections and lowering responses to vaccinations by immune suppression 
(Segalés, 2012). Today, inactivated and recombinant baculovirus-based subunit 
vaccines are commercially available to reduce the losses caused by PCV2. Be-
side these, other experimental vaccines are under development to strengthen 
PCV2-specific immune responses, including modified live attenuated, DNA, 
vector and marker vaccines (Beach and Meng, 2012). 
For the production of a cheap, safe and potentially edible PCV2 subunit 
vaccine, a CMV vector based expression system has been developed, resulting in 
recombinant CMV nanoparticles carrying an immunogenic PCV2 epitope (amino 
acids 224–233 of the PCV2 capsid protein) on the surface of the coat proteins. In 
a previous study, the recombinant CMV was able to induce specific immune re-
sponse in mice and pigs when injected parenterally, causing a rise in PCV2-
specific serum antibody levels comparable to those elicited by an inactivated 
commercial PCV2 vaccine. The protection induced by the single circovirus epi-
tope expressed in CMV was able to protect piglets from PCV2 challenge infec-
tion, although at a lower rate than the inactivated vaccine which contained full 
PCV2 virions (Gellért et al., 2012). To see if immunogenicity could also be 
achieved when recombinant CMV was given orally, two in vivo experiments 
were performed. The animal experiments were carried out in accordance with the 
Guidelines for Animal Experiments of Szent István University and with EU Di-
rective 2010/63/EU (Permit Number: 22.1/1020/3/2010). 
 ORAL IMMUNOGENICITY OF A PLANT VIRUS VECTOR BASED PCV ANTIGEN 3 
Acta Veterinaria Hungarica 
In the first experiment, our purpose was to determine if the CMV virions 
were resistant to physicochemical and biological conditions specific to the gas-
trointestinal tract, and if intact antigens were able to reach lymphoid tissues in 
the mucosa where immunological priming was possible. In this pilot study we 
used 40 female, 8-week-old SPF mice (CRL: NMRI BR, Charles River, USA) 
divided into 6 groups. Group 1 (n = 5) served as negative control. Every mouse 
in Group 2 (n = 5) received purified wild-type CMV, extracted (as described by 
Lot et al., 1972) from 1 g Nicotiana benthamiana leaf material (containing ap-
proximately 0.7 mg of the virus) intraperitoneally. Each mouse in Group 3 (n = 5) 
and Group 4 (n = 10) was fed the same amount of the extracted virus. Mice in 
Groups 5 (n = 5) and 6 (n = 10) were given CMV purified from 4 g infected leaf 
material (equivalent to approximately 2.8 mg CMV per mouse) orally. Feedings 
were carried out using gavage tubes to ensure full ingestion of the exact doses. 
Injections and feedings were repeated after 14 days. Serum samples were col-
lected in Groups 1, 2, 3 and 5 every week. Five mice in Groups 4 and 6 each 
were euthanised on day 14. All remaining animals were euthanised on day 28. In 
Groups 4 and 6, mucosal fluid was collected after homogenisation of the ilea in 
0.5 ml PBS. To detect CMV-specific antibodies, indirect enzyme-linked immu-
nosorbent assay (ELISA) was used, performed on wild-type CMV-coated ELISA 
plates, using a standard ELISA protocol (Gellért et al., 2012), with the following 
modifications: twofold dilutions starting with 1:50 were applied in the case of 
sera, and CMV-specific IgG antibodies were detected by horseradish peroxidase- 
(HRPO-) labelled anti-mouse IgG conjugates (1:10,000). In the case of intestinal 
fluid samples, twofold dilutions started at 1:2, and CMV-specific IgA antibodies 
were detected using HRPO-labelled anti-mouse IgA conjugate (1:4,000). 
CMV-specific antibody levels could be measured in all immunised ani-
mals. In Group 1 (negative control), CMV-specific antibodies could not be de-
tected throughout the whole experiment. All mice were negative for CMV-
specific antibodies at the time of the first immunisation (day 0). Detectable se-
rum IgG levels appeared after one week in the positive control group, which was 
injected parenterally with the antigen. Mice in Groups 3, 4, 5 and 6 received 
CMV orally, in Groups 5 and 6 four times more virions than in Groups 3 and 4. 
This difference in the doses caused an earlier appearance of IgGs in the group 
which ingested more CMV, but had little effect on the final serum antibody ti-
tres. Mean IgG titres are shown in Fig. 1. 
In Groups 4 and 6, CMV-specific IgA levels were measured from intesti-
nal mucosal fluids on days 14 and 28. On day 14, IgA could only be detected in 
Group 6 (the mean titre was 8), where mice were immunised with antigen doses 
four times higher than mice in Group 4, where specific IgA could not be detected 
at that time. After the second immunisation, samples from both groups were 
positive, the mean levels peaking around 16 in Group 4 and 256 in Group 6. The 
higher antigen dose resulted in the earlier appearance of secretory antibodies, and 
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it even had a notable effect on the final IgA levels. These findings indicate that 
orally administered CMV antigens survive the conditions present in the digestive 
tract, and immunogenic epitopes reach immune effector cells in a form that is 
suitable for the induction of specific immune responses, which confirms the ob-
servations of Nuzzaci et al. (2010). 
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Fig. 1. Mean serum antibody titres in immunised mice. Animals in Group 1 were used as negative 
control. Mice in Group 2 were immunised with 0.7 mg cucumber mosaic virus (CMV)  
intraperitoneally. Each mouse in Groups 3 and 5 was fed 0.7 and 2.8 mg CMV, respectively.  
Injections and feedings were carried out on days 0 and 14 
 
Based on the results of the mouse immunisation trial described above and 
the pig immunisation and challenge experiment mentioned earlier (Gellért et al., 
2012), a second experiment was conducted to evaluate the oral immunogenicity 
of the recombinant CMV vaccine candidate in the target species. Two groups of 
conventional littermate piglets, from a PCV2-free herd, weaned at 4 weeks of 
age were used, five piglets in each group. Animals in Group 1 (n = 5) were fed 
50 mg purified recombinant CMV every week from the time of weaning for four 
weeks (a total of 200 mg recombinant CMV per animal). Virus preparations 
were mixed with small amounts of the regular feed given individually. Five pig-
lets in Group 2 served as negative control. Serum samples were collected 
weekly. Indirect immune fluorescence (IF) was used for PCV2-specific IgG de-
tection with FITC-conjugated antibodies (Sigma Aldrich, St. Louis, USA) di-
luted 1:400, as described by Gellért et al. (2012). 
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PCV2-specific antibodies were not detected at the time of weaning, when 
the feeding experiment started. All sera from piglets in Group 2 (negative control 
group) remained negative throughout the trial, while antibody levels in two pig-
lets in Group 1 started to rise by the end of the second week, followed by the se-
roconversion of the other three piglets in this group by week 3. The PCV2-
specific serum IgG titres are shown in Fig. 2. 
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Fig. 2. Individual (numbering of the bars refers to the number of each piglet) and mean PCV2-
specific IgG levels in the sera of piglets orally immunised with recombinant cucumber mosaic  
virus (CMV). Piglets numbered 1 to 5 were fed 50 mg recombinant CMV each at weaning and 
three more times for 3 consecutive weeks. Piglets numbered 6 to 10 were used as negative control 
and remained seronegative for PCV2; therefore, they are not indicated 
 
Similar antibody levels in piglets immunised parenterally with the same 
recombinant CMV were shown to be able to lower PCV2 virus replication, when 
piglets were challenged both orally and parenterally (Gellért et al., 2012). The 
average virus production rate in tobacco leaves is 70 mg virus per 100 g leaf ma-
terial. In this experiment, each piglet was fed a total of 200 mg recombinant viri-
ons, extracted from roughly 300 g of leaves. The feeding of this quantity of the 
infected plant mixed with regular feed should be feasible, and leaves open the 
possibility of administering higher doses if needed. The immunogenicity of viri-
ons contained by intact plant tissues needs to be studied further, but plants are 
believed to protect antigen integrity in the gastrointestinal tract (Streatfield, 2006). 
The relatively inexpensive development and production of this nanoparticle and its 
demonstrated ability to be applied orally make it a potential vaccine candidate of 
choice against PCV2. 
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